CLDX
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.
Celldex Therapeutics, Inc. (CLDX) is rated C- (2.0/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (B); its weakest is Value (F).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-11 | F (0.0) | B (3.3) | D+ (1.6) | C (2.3) | C+ (2.6) | C- (2.0) |
| 2026-11-04 | F (0.0) | C (2.3) | D+ (1.7) | C (2.4) | C+ (2.7) | D+ (1.8) |
| 2026-10-28 | F (0.0) | C (2.3) | D+ (1.7) | C (2.4) | C+ (2.7) | D+ (1.8) |
| 2026-10-21 | F (0.0) | C (2.2) | D+ (1.7) | C+ (2.8) | C+ (2.6) | C- (1.9) |
| 2026-10-14 | F (0.0) | C (2.3) | D+ (1.7) | C+ (2.7) | C+ (2.6) | C- (1.9) |